News

Biosenta has completed termination of its joint venture agreement between the Company and 19443391 Ontario Inc and issued common shares.

Biosenta Inc. announces that it has entered into an agreement to settle $1,015,088.47 of debt through issuance of 3,625,315 common shares.

Biosenta has granted an aggregate of 1,017,000 stock options.

Biosenta announces that it has granted to certain directors, officers, employees and consultants of the Company 350,000 stock options.

Biosenta confirms that the management is unaware of any material change that would account for the recent increase in market activity.

Biosenta’s stock closed at 0.75 CAD +0.37 (97.37%). This is in step with Biosenta’s strategic business plan grow the company.

Biosenta is launching a dual-action, broad-spectrum anti-microbial disinfectant to combat COVID-19 in North America.